BiotechTube
Home/Indapta Therapeutics/Mark W. Frohlich, M.D.
MW

Mark W. Frohlich, M.D.

Chief Executive Officer

Indapta Therapeutics

Therapeutic Areas

OncologyAutoimmune Diseases

Indapta Therapeutics Pipeline

DrugIndicationPhase
G-NK cells + mAbRelapsed/Refractory Non-Hodgkin's Lymphoma and Multiple MyelomaPhase 1
G-NK cellsMultiple SclerosisPhase 1

Leadership Team at Indapta Therapeutics

GD
Guy DiPierro
Chief Operating Officer & Co-Founder
RM
Ronald Martell
Chairman of the Board and Co-Founder
SK
Sungjin Kim, Ph.D.
Scientific Founder
JS
John Sunwoo, M.D.
Scientific Founder
View full Indapta Therapeutics profile